TRIM52 regulates the proliferation and invasiveness of lung cancer cells via the Wnt/β‑catenin pathway

  • Authors:
    • Xiaoyan Mu
    • Hegen Li
    • Lei Zhou
    • Weijie Xu
  • View Affiliations

  • Published online on: April 11, 2019     https://doi.org/10.3892/or.2019.7110
  • Pages: 3325-3334
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

As a major cause of cancer‑associated mortalities, lung cancer is frequently diagnosed in males and females with an incidence ratio of 2.1:1. Tripartite motif 52 (TRIM52), an E3 ubiquitin ligase, has been reported to be involved in various biological functions, including cell proliferation and invasiveness. In the present study, an elevated TRIM52 level was observed in tumor tissues of patients with lung cancer and in lung cancer cell lines. The downregulation of TRIM52 in lung cancer cells significantly suppressed the proliferation of lung cancer cells, arrested the cell cycle at the G1 phase and was accompanied by a decrease in the levels of β‑catenin, proliferating cell nuclear antigen, c‑Myc and Cyclin D1 proteins. Additionally, TRIM52‑induced cell proliferation and invasiveness, as well as the levels of cell cycle‑associated proteins, were completely counteracted by the Wnt/β‑catenin inhibitor XAV939. Based on these data, it was speculated that TRIM52 is critical for lung cancer progression and that downregulation of TRIM52 could inhibit cell proliferation by blocking cell cycle progression. It was also speculated that TRIM52 upregulation promotes proliferation and invasiveness through activation of the Wnt/β‑catenin pathway. Thus, TRIM52 has the potential to be a therapeutic target for lung cancer.

References

1 

Ferlay J, Shin H, Bray F, Forman D, Mathers C and Parkin D: GLOBOCAN, 2008 V1. 2, cancer incidence and mortality Worldwide. IARC Cancer Base. 10:2010.

2 

Bray F, Jemal A, Grey N, Ferlay J and Forman D: Global cancer transitions according to the Human Development Index (2008–2030): A population-based study. Lancet Oncol. 13:790–801. 2012. View Article : Google Scholar : PubMed/NCBI

3 

Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. Ca Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI

4 

Herbst RS, Heymach JV and Lippman SM: Lung cancer. N Engl J Med. 359:1367–1380. 2008. View Article : Google Scholar : PubMed/NCBI

5 

Blandin Knight S, Crosbie PA, Balata H, Chudziak J, Hussell T and Dive C: Progress and prospects of early detection in lung cancer. Open Biol. 7(pii): 1700702017. View Article : Google Scholar : PubMed/NCBI

6 

National Center for Chronic Disease Prevention Health Promotion (US) Office on Smoking Health, . The health consequences of Smoking-50 years of progress: A report of the surgeon general. Atlanta (GA): Centers for Disease Control and Prevention (US); 2014

7 

Stockwell HG, Goldman AL, Lyman GH, Noss CI, Armstrong AW, Pinkham PA, Candelora EC and Brusa MR: Enviromental tobacco smoke and lung cancer risk in nonsmoking women. J Natl Cancer Inst. 84:1417–1422. 1992. View Article : Google Scholar : PubMed/NCBI

8 

Boffetta P, Agudo A, Ahrens W, Benhamou E, Benhamou S, Darby SC, Ferro G, Fortes C, Gonzalez CA, Jöckel KH, et al: Multicenter case-control study of exposure to environmental tobacco smoke and lung cancer in europe. J Natl Cancer Inst. 90:1440–1450. 1998. View Article : Google Scholar : PubMed/NCBI

9 

Kiyohara C, Wakai K, Mikami H, Sido K, Ando M and Ohno Y: Risk modification by CYP1A1 and GSTM1 polymorphisms in the association of environmental tobacco smoke and lung cancer: A case-control study in Japanese nonsmoking women. Int J Cancer. 107:139–144. 2003. View Article : Google Scholar : PubMed/NCBI

10 

Nana-Sinkam SP and Powell CA: Molecular biology of lung cancer: Diagnosis and management of lung cancer, 3rd edition: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143 (5 Suppl). e30S–e39S. 2013. View Article : Google Scholar

11 

Nguyen DX, Chiang AC, Zhang HF, Kim JY, Kris MG, Ladanyi M, Gerald WL and Massagué J: WNT/TCF Signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell. 138:51–62. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D and Rabbani SA: Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: Potential pathogenetic and prognostic implications. Cancer. 101:1345–1356. 2004. View Article : Google Scholar : PubMed/NCBI

13 

Zhang WM, Lo Muzio L, Rubini C and Yan G: Effect of WNT-1 on beta-catenin expression and its relation to Ki-67 and tumor differentiation in oral squamous cell carcinoma. Oncol Rep. 13:1095–1099. 2005.PubMed/NCBI

14 

Xu X, Sun PL, Li JZ, Jheon S, Lee CT and Chung JH: Aberrant Wnt1/β-catenin expression is an independent poor prognostic marker of non-small cell lung cancer after surgery. J Thorac Oncol. 6:716–724. 2011. View Article : Google Scholar : PubMed/NCBI

15 

He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science. 281:1509–1512. 1998. View Article : Google Scholar : PubMed/NCBI

16 

Tetsu O and Mccormick F: Beta-catenin regulates expression of Cyclin D1 in colon carcinoma cells. Nature. 398:422–426. 1999. View Article : Google Scholar : PubMed/NCBI

17 

Hatakeyama S: TRIM family proteins: Roles in autophagy, immunity, and carcinogenesis. Trends Biochem Sci. 42:297–311. 2017. View Article : Google Scholar : PubMed/NCBI

18 

Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, et al: The tripartite motif family identifies cell compartments. EMBO J. 20:2140–2151. 2001. View Article : Google Scholar : PubMed/NCBI

19 

Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM and James LC: Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Natl Acad Sci USA. 107:19985–19990. 2010. View Article : Google Scholar : PubMed/NCBI

20 

Jiang T, Tang HM, Lu S, Yan DW, Yang YX and Peng ZH: Up-regulation of tripartite motif-containing 29 promotes cancer cell proliferation and predicts poor survival in colorectal cancer. Med Oncol. 30:7152013. View Article : Google Scholar : PubMed/NCBI

21 

Ren H, Xu Y, Wang Q, Jiang J, Wudumuli, Hui L, Zhang Q, Zhang X, Wang E, Sun L and Qiu X: E3 ubiquitin ligase tripartite motif-containing 71 promotes the proliferation of non-small cell lung cancer through the inhibitor of kappaB-α/nuclear factor kappaB pathway. Oncotarget. 9:10880–10890. 2017.PubMed/NCBI

22 

Yamada Y, Takayama KI, Fujimura T, Ashikari D, Obinata D, Takahashi S, Ikeda K, Kakutani S, Urano T, Fukuhara H, et al: A novel prognostic factor TRIM44 promotes cell proliferation and migration, and inhibits apoptosis in testicular germ cell tumor. Cancer Sci. 108:32–41. 2016. View Article : Google Scholar : PubMed/NCBI

23 

Zhang Z, Xu C, Zhang X, Huang L, Zheng C, Chen H, Wang Y, Ju H and Yao Q: TRIM11 upregulation contributes to proliferation, invasion, and EMT of hepatocellular carcinoma cells. Oncol Res. 25:691–699. 2017. View Article : Google Scholar : PubMed/NCBI

24 

Dükel M, Streitfeld WS, Tang TCC, Backman LR, Ai L, May WS and Brown KD: The breast cancer tumor suppressor TRIM29 is expressed via ATM-dependent signaling in response to hypoxia. J Biol Chem. 291:21541–21552. 2016. View Article : Google Scholar : PubMed/NCBI

25 

Groner AC, Cato L, de Tribolet-Hardy J, Bernasocchi T, Janouskova H, Melchers D, Houtman R, Cato ACB, Tschopp P, Gu L, et al: TRIM24 is an oncogenic transcriptional activator in prostate cancer. Cancer Cell. 29:846–858. 2016. View Article : Google Scholar : PubMed/NCBI

26 

Li Y, Ma C, Zhou T, Liu Y, Sun L and Yu Z: TRIM65 negatively regulates p53 through ubiquitination. Biochem Biophys Res Commun. 473:278–282. 2016. View Article : Google Scholar : PubMed/NCBI

27 

Wang XL, Shi WP, Shi HC, Lu SC, Wang K, Sun C, He JS, Jin WG, Lv XX, Zou H, et al: Knockdown of TRIM65 inhibits lung cancer cell proliferation, migration and invasion: A therapeutic target in human lung cancer. Oncotarget. 7:81527–81540. 2016.PubMed/NCBI

28 

Li H, Zhang Y, Zhang Y, Bai X, Peng Y and He P: TRIM31 is downregulated in non-small cell lung cancer and serves as a potential tumor suppressor. Tumour Biol. 35:5747–5752. 2014. View Article : Google Scholar : PubMed/NCBI

29 

Malfavon-Borja R, Sawyer SL, Wu LI, Emerman M and Malik HS: An evolutionary screen highlights canonical and noncanonical candidate antiviral genes within the primate TRIM gene family. Genome Biol Evol. 5:2141–2154. 2013. View Article : Google Scholar : PubMed/NCBI

30 

Zhang Y, Wu SS, Chen XH, Tang ZH, Yu YS and Zang GQ: Tripartite motif containing 52 (TRIM52) promotes cell proliferation in hepatitis B virus-associated hepatocellular carcinoma. Med Sci Monit. 23:5202–5210. 2017. View Article : Google Scholar : PubMed/NCBI

31 

Zhang Y, Tao R, Wu SS, Xu CC, Wang JL, Chen J, Yu YS, Tang ZH, Chen XH and Zang GQ: TRIM52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of PPM1A. J Exp Clin Cancer Res. 37:1162018. View Article : Google Scholar : PubMed/NCBI

32 

Yang W, Liu L, Li C, Luo N, Chen R, Li L, Yu F and Cheng Z: TRIM52 plays an oncogenic role in ovarian cancer associated with NF-κB pathway. Cell Death Dis. 9:9082018. View Article : Google Scholar : PubMed/NCBI

33 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

34 

Hong J, Kang B, Kim A, Hwang S, Ahn J, Lee S, Kim J, Park JH and Cheon DS: Development of a highly sensitive real-time one step RT-PCR combined complementary locked primer technology and conjugated minor groove binder probe. Virol J. 8:3302011. View Article : Google Scholar : PubMed/NCBI

35 

Vogelstein B and Kinzler KW: Cancer genes and the pathways they control. Nat Med. 10:789–799. 2004. View Article : Google Scholar : PubMed/NCBI

36 

Nguyen VN, Mirejovský P, Mirejovský T, Melínová L and Mandys V: Expression of Cyclin D1, Ki-67 and PCNA in non-small cell lung cancer: Prognostic significance and comparison with p53 and bcl-2. Acta Histochem. 102:323–338. 2000. View Article : Google Scholar : PubMed/NCBI

37 

Woods AL, Hall PA, Shepherd NA, Hanby AM, Waseem NH, Lane DP and Levison DA: The assessment of proliferating cell nuclear antigen (PCNA)immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S + G2 + M phase fraction (flow cytometric analysis) and prognosis. Histopathology. 41:165–171. 2002.PubMed/NCBI

38 

Yu CC, Hall PA, Fletcher CD, Camplejohn RS, Waseem NH, Lane DP and Levison DA: Haemangiopericytomas: The prognostic value of immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen (PCNA). Histopathology. 19:29–33. 1991. View Article : Google Scholar : PubMed/NCBI

39 

Tian XH, Hou WJ, Fang Y, Fan J, Tong H, Bai SL, Chen Q, Xu H and Li Y: XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt/β-catenin signaling pathway. J Exp Clin Cancer Res. 32:1002013. View Article : Google Scholar : PubMed/NCBI

40 

Lu P, Wang Y, Liu X, Wang H, Zhang X, Wang K, Wang Q and Hu R: Malignant gliomas induce and exploit astrocytic mesenchymal-like transition by activating canonical Wnt/β-catenin signaling. Med Oncol. 33:662016. View Article : Google Scholar : PubMed/NCBI

41 

Lim JH, Park JW and Chun YS: Human arrest defective 1 acetylates and activates beta-catenin, promoting lung cancer cell proliferation. Cancer Res. 66:10677–10682. 2006. View Article : Google Scholar : PubMed/NCBI

42 

Rui X, Hu J, Zhang T, Chao J and Wang HY: TRIM29 overexpression is associated with poor prognosis and promotes tumor progression by activating Wnt/β-catenin pathway in cervical cancer. Oncotarget. 7:28579–28591. 2016.PubMed/NCBI

43 

Kim PY, Tan O, Liu B, Trahair T, Liu T, Haber M, Norris MD, Marshall GM and Cheung BB: High TDP43 expression is required for TRIM16-induced inhibition of cancer cell growth and correlated with good prognosis of neuroblastoma and breast cancer patients. Cancer Lett. 374:315–323. 2016. View Article : Google Scholar : PubMed/NCBI

44 

Lee OH, Lee J, Lee KH, Woo YM, Kang JH, Yoon HG, Bae SK, Songyang Z, Oh SH and Choi Y: Role of the focal adhesion protein TRIM15 in colon cancer development. Biochim Biophys Acta. 1853:409–421. 2015. View Article : Google Scholar : PubMed/NCBI

45 

Watanabe M and Hatakeyama S: TRIM proteins and diseases. J Biochem. 161:135–144. 2017.PubMed/NCBI

46 

Zhan W, Han T, Zhang C, Xie C, Gan M, Deng K, Fu M and Wang JB: TRIM59 promotes the proliferation and migration of non-small cell lung cancer cells by upregulating cell cycle related proteins. PLoS One. 10:e01425962015. View Article : Google Scholar : PubMed/NCBI

47 

Hart T, Chandrashekhar M, Aregger M, Steinhart Z, Brown KR, Macleod G, Mis M, Zimmermann M, Fradet-Turcotte A, Sun S, et al: High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities. Cell. 163:1515–1526. 2015. View Article : Google Scholar : PubMed/NCBI

48 

Wang T, Birsoy K, Hughes NW, Krupczak KM, Post Y, Wei JJ, Lander ES and Sabatini DM: Identification and characterization of essential genes in the human genome. Science. 350:1096–1101. 2015. View Article : Google Scholar : PubMed/NCBI

49 

Peifer M and Polakis P: Wnt signaling in oncogenesis and embryogenesis-a look outside the nucleus. Science. 287:1606–1609. 2000. View Article : Google Scholar : PubMed/NCBI

50 

You Z, Saims D, Chen S, Zhang Z, Guttridge DC, Guan K, Macdougald OA, Brown AM, Evan G, Kitajewski J and Wang CY: Wnt signaling promotes oncogenic transformation by inhibiting c-Myc-induced apoptosis. J Cell Biol. 157:429–440. 2002. View Article : Google Scholar : PubMed/NCBI

51 

Brown AM: Wnt signaling in breast cancer: Have we come full circle? Breast Cancer Res. 3:351–355. 2001. View Article : Google Scholar : PubMed/NCBI

52 

Jiang X, Tan J, Li J, Kivimäe S, Yang X, Zhuang L, Lee PL, Chan MT, Stanton LW, Liu ET, et al: DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 13:529–541. 2008. View Article : Google Scholar : PubMed/NCBI

53 

Miller DM, Thomas SD, Islam A, Muench D and Sedoris K: c-Myc and cancer metabolism. Clin Cancer Res. 18:5546–5553. 2012. View Article : Google Scholar : PubMed/NCBI

54 

Hall M and Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res. 68:67–108. 1996. View Article : Google Scholar : PubMed/NCBI

55 

Yu Q, Geng Y and Sicinski P: Specific protection against breast cancers by Cyclin D1 ablation. Nature. 411:1017–1021. 2001. View Article : Google Scholar : PubMed/NCBI

56 

Lukas J, Bartkova J, Rohde M, Strauss M and Bartek J: Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity. Mol Cell Biol. 15:2600–2611. 1995. View Article : Google Scholar : PubMed/NCBI

57 

Griffey SM, Kraegel SA and Madewell BR: Proliferation indices in spontaneous canine lung cancer: Proliferating cell nuclear antigen (PCNA), Ki-67 (MIB1) and mitotic counts. J Comp Pathol. 120:321–332. 1999. View Article : Google Scholar : PubMed/NCBI

58 

Celis JE and Celis A: Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: Subdivision of S phase. Proc Natl Acad Sci USA. 82:3262–3266. 1985. View Article : Google Scholar : PubMed/NCBI

59 

Bravo R, Frank R, Blundell PA and Macdonaldbravo H: Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature. 326:515–517. 1987. View Article : Google Scholar : PubMed/NCBI

60 

Benke S, Agerer B, Haas L, Stöger M, Lercher A, Gabler L, Kiss I, Scinicariello S, Berger W, Bergthaler A, et al: Human tripartite motif protein 52 is required for cell context-dependent proliferation. Oncotarget. 9:13565–13581. 2018. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 41 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Mu, X., Li, H., Zhou, L., & Xu, W. (2019). TRIM52 regulates the proliferation and invasiveness of lung cancer cells via the Wnt/β‑catenin pathway. Oncology Reports, 41, 3325-3334. https://doi.org/10.3892/or.2019.7110
MLA
Mu, X., Li, H., Zhou, L., Xu, W."TRIM52 regulates the proliferation and invasiveness of lung cancer cells via the Wnt/β‑catenin pathway". Oncology Reports 41.6 (2019): 3325-3334.
Chicago
Mu, X., Li, H., Zhou, L., Xu, W."TRIM52 regulates the proliferation and invasiveness of lung cancer cells via the Wnt/β‑catenin pathway". Oncology Reports 41, no. 6 (2019): 3325-3334. https://doi.org/10.3892/or.2019.7110